Efficacy of Low-Dose Tamsulosin on???Lower Urinary Tract Symptoms???Suggestive of Benign???Prostatic Hyperplasia

Park, Choal Hee; Chang, Hyuk Soo; Oh, Bong Ryul; Kim, Hyung Jee; Sul, Chong Koo; Chung, Sung Kwang; Jung, Sang-Yong

doi:10.2165/00044011-200424010-00005

Cited by 43 publications

(44 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The standard dose of tamsulosin for BPH is 0.4 mg (8) but a lower dose (0.2 mg) is also used in Asia (10,11). The conventional Tamsulosin formulation has an absorption profile that is dependent on food intake, and is associated with low levels of intestinal absorption.…”

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study

Lojanapiwat

Permpongkosol

2011

Int. braz j urol.

View full text Add to dashboard Cite

Aims: Tamsulosin, a superselective subtype alpha 1a and 1d blocker, is used for the treatment of male Lower Urinary Tract Symptoms (LUTS) commonly caused by Benign Prostatic Hyperplasia (BPH). This prospective study evaluated the efficacy and safety of a new formulation, Tamsulosin OCAS® (Oral Controlled Absorption System), for LUTS associated with BPH in Thai patients. Materials and Methods: Fifty one patients over 40 years old with complaints of LUTS associated with BPH were recruited. Patients received an 8 week course of once daily 0.4 mg tamsulosin OCAS®, and were followed up at 2 (visit 3), 4 (visit 4) and 8 (visit 5) weeks post-treatment. At each visit, patients were assessed using the International Prostate Symptom Score (IPSS), Nocturia Quality of Life (N-QoL) Questionnaire, QoL Assessment Index (IPSS-QoL), and International Index of Erectile Function (IIEF). The primary outcome was efficacy of Tamsulosin. The secondary outcomes included change in the mean number of nocturia episodes, hours of undisturbed sleep (HUS) and uroflowmetry measurements. Results: Total IPSS significantly decreased at week 8 from baseline (from 19.52 to 6.08; p < 0.001). Similarly, the voiding and storage subscores of IPSS also continued to improve significantly starting from the second and third visits, respectively (p < 0.001 versus baseline). The IPSS-QoL and N-QoL scores significantly improved at visit 3 through end of study. In addition, we observed significant nocturia and HUS improvement in their last clinic visit. Uroflowmetry parameters, Q max and Q ave , improved significantly at 3 rd clinic visit . Three patients experienced mild dizziness. Conclusion: Tamsulosin OCAS® treatment led to significant improvements in LUTS, HUS and QoL in Thai patients with bladder outlet obstruction from BPH with few side effects.

show abstract

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study

Lojanapiwat

Permpongkosol

2011

Int. braz j urol.

View full text Add to dashboard Cite

show abstract

“…Studies have demonstrated the efficacy of doxazosin, tamsulosin and terazosin in populations (n ¼ 27-205) including Korean, Japanese and Chinese men. [30][31][32][33][34][35] These studies used a dose of 0.2 mg tamsulosin, whereas the CombAT study used 0.4 mg, with no unexpected safety or tolerability issues compared to studies using the 0.2 mg dose. Efficacy of the 5ARI finasteride has also been studied in Asian men, demonstrating reduced prostate volume, and improvement in symptoms and Q max at 6 months and 1 year.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH

Chung

Roehrborn

Siami³

et al. 2008

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Although ethnicity-based differences in prostate size and physiology have been reported, results of benign prostatic hyperplasia (BPH) treatment trials in predominantly Caucasian patients are assumed to be applicable to non-Caucasian populations. This post hoc analysis investigated whether an Asian subpopulation of men with moderate-to-severe BPH in the CombAT study achieves treatment responses in line with those of the overall study population. In this doubleblind, randomized, parallel-group trial, 325 Asian men were assigned to treatment with 0.5 mg dutasteride once daily, 0.4 mg tamsulosin once daily or the combination. Decrease in international prostate symptom score (IPSS) at month 24 from baseline (the primary endpoint) was significantly greater with combination treatment compared with tamsulosin (Po0.05), and numerically, but not statistically significantly, greater compared with dutasteride. Mean IPSS was reduced from baseline by 7.5 (±0.84) in the combination group, by 6.3 (±0.86) in the dutasteride group and by 4.5 (±0.78) in the tamsulosin group, resulting in respective mean IPSS at months 24 of 11.4 (±0.60), 12.7 (±0.70) and 14.3 ( ± 0.74). The adverse event profile was similar to that observed in the overall CombAT population, and drug-related adverse events were more common with combination therapy (26%) than with tamsulosin (15%) or dutasteride (9%). No unexpected adverse events emerged. In conclusion, in Asian men with moderate-to-severe lower urinary tract symptoms and an enlarged prostate, combination therapy achieved significantly greater improvements from baseline BPH symptoms, flow rate, quality of life, reduced prostate volume and improved treatment satisfaction compared with tamsulosin monotherapy.

show abstract

“…10 Nevertheless, the prevalence of EjD (0.6%-4.5%) and of overall adverse events (6.2%) after 0.2 mg OD tamsulosin in South Korea is considerably lower than in Europe and the United States. 11,12 However, in the studies mentioned above, EjD was not clearly defined or was sometimes reported as retrograde ejaculation. Furthermore, the degree of dysfunction has not been subject to study.…”

Section: Introductionmentioning

confidence: 99%

Effect of tamsulosin on ejaculatory function in BPH/LUTS

Song¹,

Son²,

Kim³

et al. 2011

Asian J Androl

View full text Add to dashboard Cite

This study was undertaken to determine the impact on ejaculatory function of tamsulosin (0.2 mg) given once daily (OD) for 12 weeks and to identify risk factors for ejaculatory dysfunction in patients undergoing this treatment. Males with an International Prostatic Symptom Score (IPSS) o8 were enrolled in this study. All participants completed questionnaires, including the IPSS and the Male Sexual Health Questionnaire (MSHQ), and serum prostate-specific antigen, transrectal ultrasound and uroflowmetry with post-void residual were measured. After initiating 0.2 mg OD tamsulosin, patients were re-evaluated on the fourth and twelfth weeks of medication. The chi-squared test, the independent t-test and one-way ANOVA were used to compare means. Binary logistic regression analysis was used to calculate the odds ratio for all risk factors. A total of 177 men constituted the study cohort. No significant difference was observed between baseline and follow-up for the erectile function, ejaculatory function, satisfaction, sexual activity and desire domains (EFD, EjFD, SDA and ADD) or for erectile or ejaculatory bother mean scores. After 12 weeks, the overall incidence of ejaculatory dysfunction (EjD) was 13.4%. Incidences of the seven different types of EjD (decreased frequency, delay, dryness, decreased strength/force, decreased volume, decreased pleasure and pain at ejaculation) were 2.4%, 3.1%, 3.9%, 3.9%, 6.3%, 7.1% and 3.1%, respectively. Baseline EjFD scores were higher for IPSS responders than for non-responders (26.09 vs. 24.06, P50.03). An EjFD score reduction was more frequent in IPSS responders. The incidence of EjD was small, but not negligible and was more frequent in patients with less lower urinary tract symptoms, a smaller prostate, higher baseline MSHQ totals and higher EjFD scores.

show abstract

Efficacy of Low-Dose Tamsulosin on???Lower Urinary Tract Symptoms???Suggestive of Benign???Prostatic Hyperplasia

Abstract: One-year treatment with tamsulosin 0.2 mg/day in Korean patients with suspected BPH was well tolerated and effective in improving LUTS and urinary flow. The effect on symptoms was apparent after 12 weeks of treatment, and symptom improvement was observed for up to 1 year.

Cited by 43 publications

References 20 publications

The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study

The efficacy and safety of oral Tamsulosin controlled absorption system (OCAS) for the treatment of lower urinary tract symptoms due to bladder outlet obstruction associated with benign prostatic hyperplasia: an open-label preliminary study

Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH

Effect of tamsulosin on ejaculatory function in BPH/LUTS

Contact Info

Product

Resources

About